logo
welcome
Investor's Business Daily

Investor's Business Daily

Alnylam stock tumbles after Pfizer-rivaling heart disease treatment fails in study

Investor's Business Daily
Summary
Nutrition label

75% Informative

Alnylam Pharmaceuticals' drug, vutrisiran, tested its drug in patients with ATTR amyloidosis with cardiomyopathy.

After 30 months , patients were 13.8% less likely to die of any cause.

But investors were looking for a 32% risk reduction after 30 months .

Pfizer 's Vyndaqel , an approved treatment, brought in $3.32 billion in sales last year .

VR Score

75

Informative language

79

Neutral language

51

Article tone

formal

Language

English

Language complexity

46

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links